This is a prospective, multicentric, non comparative study aiming to evaluate theclinical and virological evolution of high-risk patients infected with SARS-CoV-2 treatedwithtin the framework of a cohort ATU ('Autorisation temporaire d'utilisation') orauthorisation for early access (AAP) delivered by the French drug agency (ANSM).
Not Provided
Other: biobank
- Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the
first 100 participants) (serum, plasma and whole blood)
- For participants in the immunological ancillary study: additional blood sampling at
Day 0, Day 7 and Month 1 (PBMC)
- Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive
respectively at Day 7 and Day 14)
- Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5
Inclusion Criteria:
- Adults with the criteria for COVID-19 treatment within the French compassionate
program (ATU/AAP)
- Adults covered by the French social health coverage
- Adults who signed the informed consent form
Exclusion Criteria:
- Exclusion criteria described in the French compassionate program (ATU/AAP)
- Patient participating in another biomedical research with an exclusion period
ongoing at inclusion
- Vulnerable patient (adults legally protected: under judicial protection,
guardianship, or supervision, persons deprived of their liberty)
- Pregnant or breastfeeding woman
CH Agen-Nerac
Agen, France
CHU d'Angers
Angers, France
CHR Metz-Thionville
Ars-Laquenexy, France
Hôpital Avicenne
Bobigny, France
CHU de Bordeaux
Bordeaux, France
CHU Gabriel Montpied
Clermont-Ferrand, France
Centre Hospitalier Sud Francilien - Hématologie
Corbeil-Essonnes, France
Centre Hospitalier Sud Francilien - Néphrologie
Corbeil-Essonnes, France
CHU de Dijon
Dijon, France
CHU de Martinique
Fort-de-France, France
Hôpital Bicêtre - Médecine interne
Le Kremlin-Bicêtre, France
Hôpital Bicêtre - SMIT
Le Kremlin-Bicêtre, France
CHU de Limoges
Limoges, France
Hospices Civils de Lyon (HCL)
Lyon, France
CHU de Montpellier
Montpellier, France
CHRU de Nancy
Nancy, France
CHU de Nantes
Nantes, France
CHU de Nîmes
Nîmes, France
Hôpital Lariboisière - SMIT
Paris, France
Hôpital Saint Antoine
Paris, France
Hôpital Bichat Claude-Bernard
Paris, France
Hôpital Tenon
Paris, France
Hôpital Bichat Claude-Bernard - SAU
Paris, France
Hôpital Lariboisière - SAU SMUR
Paris, France
Hôpital Pitié-Salpêtrière
Paris, France
Hôpital Saint Antoine - SAU
Paris, France
Hôpital Saint-Louis
Paris, France
Hôpital Universitaire Necker Enfants Malades
Paris, France
Hôpitaux Cochin - Port Royal
Paris, France
CHI Poissy St Germain en Laye
Poissy, France
CHU de Poitiers
Poitiers, France
CHU de Rennes
Rennes, France
CH de Tarbes
Tarbes, France
CHU de Toulouse - IUCT - Oncopole
Toulouse, France
CHU de Toulouse
Toulouse, France
CH de Tourcoing
Tourcoing, France
CHRU de Tours - Hôpital Bretonneau
Tours, France
Youri Yordanov, Dr
01 71 97 08 69
youri.yordanov@aphp.fr
Guillaume Martin-Blondel, Pr
05 61 77 96 99
martin-blondel.g@chu-toulouse.fr
Youri Yordanov, Dr, Principal Investigator
Saint Antoine Hospital